QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Google Scholar Articles by Papadopoulos, N. Articles by Kikilas, A. PubMed PubMed Citation Articles by Papadopoulos, N. Articles by Kikilas, A.

Hyperchloremic Metabolic Acidosis Due to Deferasirox in a Patient with Beta Thalassemia Major

Internist, 2nd Department of Internal Medicine, 401 General Army Hospital of Athens, Greece

Aresti Vasiliki, MD

Internist, 2nd Department of Internal Medicine, 401 General Army Hospital of Athens

Georgios Aloizos, MD

Internist, 2nd Department of Internal Medicine, 401 General Army Hospital of Athens

Petros Tapinis, MD

Internist, 2nd Department of Internal Medicine, 401 General Army Hospital of Athens

Athanasios Kikilas, MD

Internist, Specialist in Infectious Diseases, Head, 2nd Department of Internal Medicine, 401 General Army Hospital of Athens

Reprints: Dr. Papadopoulos, 2nd Department of Internal Medicine, 401 General Army Hospital of Athens, Greece, fax 302104228009, npnck7{at}yahoo.com

OBJECTIVE: To report a case of hyperchloremic metabolic acidosis in a patient with beta thalassemia major secondary to treatment with deferasirox due to iron overload.

CASE SUMMARY: A 58-year-old white female with beta thalassemia major was admitted with fever, fatigue, abnormal liver function test results, and hyperchloremic metabolic acidosis (lactate dehydrogenase 494 U/L, aspartate aminotransferase 167 U/L, alanine aminotransferase 250 U/L, -glutamyl transferase 102 U/L, total bilirubin 3.79 mg/dL, direct bilrubin 2.37, potassium 3.3 mEq/L, PO₂ 81.4 mm Hg, PCO₂ 29.4 mm Hg, HCO₃ 16 mEq/L, pH 7.35, chloride 116 mEq/L, anion gap 7.5 mEq/L). Twenty-five days before admission the patient decided to discontinue treatment with deferoxamine for chronic iron overload and continue treatment with oral deferasirox 1500 mg/day. Despite extended clinical and laboratory examination, no obvious cause of fever, hepatitis, or hyperchloremic metabolic acidosis was revealed. Diagnosis was compatible with tubular dysfunction, drug-induced hepatitis, and hypersensitivity reaction due to deferasirox. All pathological findings were fully reversible and our patient had an excellent outcome.

DISCUSSION: The presence of tubular dysfunction should be considered in any patient with otherwise unexplained hyperchloremic metabolic acidosis. In our patient, other potential causes of metabolic hyperchloremic acidosis were ruled out. Toxic effects of deferasirox are probably caused by chelation of mitochondrial iron, leading to adenosine triphosphate depletion in tubular epithelial cells. Use of the Naranjo probability scale revealed that the adverse reaction was probable.

CONCLUSIONS: Kidney toxicity may be a major issue in the management of patients receiving deferasirox. Our case indicates a potential risk of renal toxicity with the presence of tubular dysfunction and hyperchloremic metabolic acidosis in patients undergoing treatment with deferasirox.

Key Words: deferasirox, deferoxamine, hyperchloremic metabolic acidosis, iron, renal toxicity

Published Online, November 24, 2009. www.theannals.com, DOI 10.1345/aph.1M440